scholarly journals Indoxyl Sulfate Impairs Endothelial Progenitor Cells and Might Contribute to Vascular Dysfunction in Patients with Chronic Kidney Disease

2016 ◽  
Vol 41 (6) ◽  
pp. 1025-1036 ◽  
Author(s):  
Cheng-Jui Lin ◽  
Chih-Jen Wu ◽  
Pei-Chen Wu ◽  
Chi-Feng Pan ◽  
Tuan-Jen Wang ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Vascular Dysfunction ◽  
Indoxyl Sulfate ◽  
Endothelial Progenitor

scholarly journals Effect of darbepoetin alfa on endothelial progenitor cells and vascular reactivity in chronic kidney disease

2011 ◽  
Vol 16 (3) ◽  
pp. 183-189 ◽  
Author(s):  
Emile R Mohler ◽  
Lifeng Zhang ◽  
Elizabeth Medenilla ◽  
Wade Rogers ◽  
Benjamin French ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Darbepoetin Alfa ◽  
Vascular Reactivity ◽  
Endothelial Progenitor

scholarly journals Endothelial Progenitor Cells and Cardiovascular Events in Patients with Chronic Kidney Disease – a Prospective Follow-Up Study

PLoS ONE ◽  
2010 ◽  
Vol 5 (7) ◽  
pp. e11477 ◽  
Author(s):  
Johan Lorenzen ◽  
Sascha David ◽  
Ferdinand H. Bahlmann ◽  
Kirsten de Groot ◽  
Elisabeth Bahlmann ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Cardiovascular Events ◽  
Endothelial Progenitor ◽  
Follow Up Study

Imbalance between Detached Circulating Endothelial Cells and Endothelial Progenitor Cells in Chronic Kidney Disease

2006 ◽  
Vol 24 (2) ◽  
pp. 196-202 ◽  
Author(s):  
Ernesto Rodríguez-Ayala ◽  
Qiang Yao ◽  
Carolina Holmén ◽  
Bengt Lindholm ◽  
Suchitra Sumitran-Holgersson ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Endothelial Cells ◽  
Kidney Disease ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Circulating Endothelial Cells ◽  
Endothelial Progenitor

scholarly journals Linagliptin, when compared to placebo, improves CD34+ve Endothelial Progenitor Cells in Type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin, a randomized controlled trial.

2020 ◽  
Author(s):  
Hassan B Awal ◽  
Seshagiri Rao Nandula ◽  
Cleyton C Domingues ◽  
Fiona J Dore ◽  
Nabanita Kundu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Arterial Stiffness ◽  
Progenitor Cells ◽  
Endothelial Progenitor Cells ◽  
Risk Indicator ◽  
Cvd Risk ◽  
Endothelial Progenitor

Abstract Introduction: Endothelial Progenitor cells (EPCs) has been shown to be dysfunctional in both Type 2 Diabetes and Chronic Kidney Disease (CKD) leading to poor regeneration of endothelium and renal perfusion. EPCs have been shown to be a robust cardiovascular disease (CVD) risk indicator. Cellular mechanisms of DPP4 inhibitors such as Linagliptin (LG) on CVD risk, in patients with Type 2 Diabetes with established CKD has notbeen established. Hypothesis : Linagliptin, a DPP4 inhibitor when added to insulin, metformin or both may improve endothelial dysfunction in a diabetic kidney disease (DKD) population. Methods : 31 subjects taking metformin and/or Insulin were enrolled in this 12 weeks, double blind, randomized placebo matched trial, with 5 mg LG compared to placebo. Type 2 diabetes subjects (30-70 years old), HbA1c of 6.5-10%, CKD Stage 1-3 were included. CD34+ cell number, migratory function, gene expression along with vascular parameters such as Arterial stiffness, biochemistry, resting energy expenditure and body composition were measured. Data were collected at week 0, 6 and 12. A mixed model regression analysis was done with p value <0.05 considered significant. Results : A double positive CD34/CD184 cell count had a statistically significant increase (p<0.02) as determined by flow cytometry in LG group where CD184 is SDF1a cell surface receptor. Though mRNA differences in CD34+ve was more pronounced CD34- cell mRNA analysis showed increase in antioxidants (SOD2, Catalase and CPX) and prominent endothelial markers (PECAM1, VEGF-A, vWF and NOS3). Arterial stiffness measures such as augmentation Index (AI) (p<0.04) and pulse wave analysis (PWV) were improved (reduced in stiffness) in LG group. A reduction in LDL: HDL ratio was noted in treatment group (p <0.04). Urinary exosome protein examining podocyte health (Podocalxyin, Wilms tumor and Nephrin) showed reduction or improvement. Conclusions : In DKD subjects, Linagliptin promotes an increase in CXCR4 expression on CD34+ progenitor cells with a concomitant improvement in vascular and renal parameters at 12 weeks

Sign in / Sign up

Export Citation Format

Share Document